Onkologie. 2025:19(2):104-107 | DOI: 10.36290/xon.2025.021

Complete remission of metastatic squamous esophageal carcinoma

Marián Liberko, Renata Soumarová
Onkologická klinika, 3. LF UK a FNKV, Praha
3. lékařská fakulta Univerzity Karlovy, Praha

Metastatic esophageal cancer is a disease with an infaust prognosis, with a median survival of approximately 12 months. New treatment options using chemotherapy in combination with immunotherapy may lead to long-term disease control and, in a small percentage of patients, complete remission. This case report describes a patient with primary metastatic disease, where chemoimmunotherapy led to rapid resolution of clinical symptoms, improvement of clinical status and ultimately to induction of a durable complete remission of the disease.

Keywords: metastatic esophageal carcinoma, immunotherapy, complete remission.

Accepted: April 25, 2025; Published: May 2, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Liberko M, Soumarová R. Complete remission of metastatic squamous esophageal carcinoma. Onkologie. 2025;19(2):104-107. doi: 10.36290/xon.2025.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 2.5.2026

    References

    1. Sun JM, Shen L, ShaH MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treat­ment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. The Lancet. 2021;398:759-771. Go to original source... Go to PubMed...
    2. Shah MA, Sun MJ, Shen L, et al. First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study. JCO. 2024;42:250-250. Go to original source...
    3. Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 2022;386:449-462. doi: 10.1056/NEJMoa2111380. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.